Predicting standard reduction potential for anticancer Au(III)-complexes: A DFT study
Authors:
- G.Y. Sánchez DelgadoGDG.Y. Sánchez Delgado
- D. PaschoalD. Paschoal
- H.F. Dos SantosHSH.F. Dos Santos
- 1 May 2017
- journal article
- research article
- Published by Elsevier in Computational and Theoretical Chemistry
- Vol. 1108, 86-92
Abstract
No abstract availableKeywords
Funding Information
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (485779/2013-7)
- Fundação de Amparo à Pesquisa do Estado de Minas Gerais
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
This publication has 28 references indexed in Scilit:
- Ligand Exchange Reaction of Au(I) R-N-Heterocyclic Carbene Complexes with CysteineThe Journal of Physical Chemistry A, 2016
- Chemical biology of anticancer gold( iii ) and gold( i ) complexesChemical Society Reviews, 2015
- Gold(III) Complexes Containing N‐Heterocyclic Carbene Ligands: Thiol “Switch‐on” Fluorescent Probes and Anti‐Cancer AgentsAngewandte Chemie International Edition, 2013
- A dinuclear cyclometalated gold(iii)–phosphine complex targeting thioredoxin reductase inhibits hepatocellular carcinoma in vivoChemical Science, 2013
- NHC Gold Halide Complexes Derived from 4,5-Diarylimidazoles: Synthesis, Structural Analysis, and Pharmacological Investigations as Potential Antitumor AgentsJournal of Medicinal Chemistry, 2011
- Gold compounds as therapeutic agents for human diseasesMetallomics, 2011
- The status of platinum anticancer drugs in the clinic and in clinical trialsDalton Transactions, 2010
- Cyclometalated gold(iii) complexes with N-heterocyclic carbene ligands as topoisomerase I poisonsChemical Communications, 2010
- The anti-cancer properties of gold(III) compounds with dianionic porphyrin and tetradentate ligandsCoordination Chemistry Reviews, 2009
- Anticancer Cyclometalated [AuIIIm(C∧N∧C)mL]n+ Compounds: Synthesis and Cytotoxic PropertiesChemistry – A European Journal, 2006